All News
Janet Pope Janetbirdope ( View Tweet)
Treat-to-Target Works in Gout With No Cardiac Toxicity
New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows that allopurinol and febuxostat may effectively lower urate levels when used in a treat-to-target approach. Importantly, both urate-lowering therapies were very effective with 90% of patients reaching target urate levels. Additionally, both appeared safe, with no evidence of increased cardiovascular toxicity (Abstract #1900).
Read ArticleIndustry Abstract Previews #ACR21 - Horizon, Aurinia, AstraZeneca
The pharmaceutical companies will feature the results of their pivotal clinical trials and data analyses at ACR Convergence 2021. Below is a listing of some of their best studies for you to review and look for in the meeting.
Read ArticleYousaf Ali MD yousafali_md ( View Tweet)
Alla Ayten alla_ajten ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast – #ACA: Ask Cush Anything (10.8.2021)
Arthritis numbers are rising, and people are finally talking about osteoarthritis. Also, ACR 2021 is just a few weeks away - are you ready? Finally, I'll review cases and questions submitted by viewers in Ask Cush Anything (#ACA). This, and nearly a dozen news items and reports, are discussed in this week's podcast. Let's begin.
Read ArticlePrevalence of Arthritis Rising in the USA
The latest CDC estimates of the national prevalence of arthritis and arthritis-attributable activity limitations (AAAL) show a continued increase in absolute number: 58.5 million (23.7%) U.S. adults have arthritis, 25.7 million (43.9%) of whom have AAAL.
Read ArticleLinks:
Gout Flare and Treatment Studies Lacking in Severe Chronic Kidney Disease
Gout is a common comorbidity amongst those with chronic kidney disease (CKD), with the added challenge of choosing best therapies in the setting of declining renal function. A systematic literature review notes significant deficiencies regarding the efficacy and safety outcom
Read ArticleStarting Febuxostat During an Acute Gout Flare
A randomized controlled trial in gout patients has shown that starting febuxostat during an acute gout flare was without ill-effects and did not prolong the gouty attack.
Read Article